Old drug, new trick: pentoxifylline may shield kidneys in ICU

NCT ID NCT07561801

First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study tested whether pentoxifylline, a drug used for blood flow issues, could prevent kidney damage caused by contrast dye in 70 ICU patients with chronic kidney disease. Participants received the drug before procedures like cardiac catheterization. Researchers tracked how many developed contrast-induced nephropathy, changes in kidney function, ICU stay length, and need for dialysis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRAST-INDUCED NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia, 31527, Egypt

Conditions

Explore the condition pages connected to this study.